Long Development Times Linked to Low Patient Accrual Rates for Cancer Trials

A recent study from Oregon Health and Science University (OHSU) indicates that 40 percent of all cancer trials do not achieve the minimum accrual goals necessary to achieve a statistically significant conclusion. Additionally, it was found that the longer the preparation time required to develop the clinical trial, the harder it was to accrue enough… Continue reading Long Development Times Linked to Low Patient Accrual Rates for Cancer Trials

Men Estimated to be 40 Percent More Likely to Die From Cancer

Overall, men are 40 percent more likely to die from cancer, according to a recent study. Additionally, men are 16 percent more likely to contract cancer in the first place. The study, which was initiated by Cancer Research UK, suggests alarmingly different expectations of cancer survival between men and women.When looking specifically at cancers that… Continue reading Men Estimated to be 40 Percent More Likely to Die From Cancer

Direct Chemo Delivery Shows Signs of Prolonging Patient Survival

Malignant gliomas are an especially difficult type of cancer to treat. Manifesting in the brain or spine, patients diagnosed with this deadly form of cancer have only a 3 percent likelihood of surviving five years or more. Now, a new method for delivering chemotherapy drugs is showing early signs of prolonging survival times among patients… Continue reading Direct Chemo Delivery Shows Signs of Prolonging Patient Survival

Headline: Lilly Gets Fourth FDA Approval for ALIMTA

A spokesperson for Eli Lilly and Co. (LLY), one of the leading US pharmaceutical manufacturers, released a statement last week that the US Food and Drug Administration (FDA) has granted a fourth approval for the cancer drug ALIMTA to be used as an upkeep therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC).… Continue reading Headline: Lilly Gets Fourth FDA Approval for ALIMTA

Protein Helps Indicate Progression of Rare Lung Disease

Idiopathic pulmonary fibrosis (IPF) is a rare lung disease with an expected survival time of about three to five years. Now, the link between a specific protein in the lungs and the progression of the illness may help doctors make better decisions about treatment methods for each individual patient. The name of the protein is… Continue reading Protein Helps Indicate Progression of Rare Lung Disease

Opioid Pain Reliever Approved for Breakthrough Pain in Cancer Patients

┬áPain is an infamously difficult cancer symptom to treat. Even when potent pain relievers are used, waves of pain often flare up and break through the effects of the medication. This type of pain is known as breakthrough pain. Now, doctors and patients have a new tool to help combat breakthrough pain. Recently, the U.S.… Continue reading Opioid Pain Reliever Approved for Breakthrough Pain in Cancer Patients

Cancer Cells Rely on Healthy Genes for Survival

Cancer cells incorporate a number of mutated genes to wreak havoc on our healthy human bodies. However, findings from a recent study now indicate that cancer cells also rely heavily on the presence of non-mutated genes for survival. Researchers at Harvard Medical School and Brigham and Women’s Hospital carried out the study. The researchers made… Continue reading Cancer Cells Rely on Healthy Genes for Survival

“Trojan Horse” Proves Effective in Lowering Cancer’s Resistance to Chemotherapy

During chemotherapy, it is not uncommon for a tumor to become resistant to treatment over time. This fact has proven to be a major obstacle in cancer treatment and, with few alternatives for treatment, patients with chemo-resistant cancer often experience limited timeframes for survival. In an effort to reduce a cancer’s ability to resist chemotherapy… Continue reading “Trojan Horse” Proves Effective in Lowering Cancer’s Resistance to Chemotherapy